Stephen Gordon Sells 15,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CFO Stephen Gordon sold 15,000 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $128.00, for a total transaction of $1,920,000.00. Following the completion of the transaction, the chief financial officer now owns 23,299 shares in the company, valued at approximately $2,982,272. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Stephen Gordon also recently made the following trade(s):

• On Monday, April 1st, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00.
• On Friday, March 8th, Stephen Gordon sold 1,903 shares of TransMedics Group stock. The stock was sold at an average price of $87.63, for a total transaction of $166,759.89.
• On Monday, March 4th, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The stock was sold at an average price of $82.80, for a total transaction of $1,242,000.00.

TransMedics Group Stock Up 1.2 %

Shares of NASDAQ:TMDX opened at $128.77 on Friday. The company has a market cap of $4.24 billion, a price-to-earnings ratio of -378.74 and a beta of 1.87. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The company has a 50-day moving average price of $89.25 and a 200 day moving average price of $79.26. TransMedics Group, Inc. has a 12 month low of $36.42 and a 12 month high of $132.96.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company had revenue of $96.90 million for the quarter, compared to the consensus estimate of $83.78 million. During the same quarter in the prior year, the company posted ($0.08) EPS. TransMedics Group’s quarterly revenue was up 132.9% on a year-over-year basis. As a group, equities research analysts predict that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

Institutional Trading of TransMedics Group

A number of hedge funds have recently bought and sold shares of TMDX. Blair William & Co. IL raised its position in shares of TransMedics Group by 15.3% in the 1st quarter. Blair William & Co. IL now owns 183,524 shares of the company’s stock worth $13,570,000 after acquiring an additional 24,417 shares in the last quarter. State Board of Administration of Florida Retirement System grew its stake in TransMedics Group by 8.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock valued at $745,000 after purchasing an additional 780 shares during the last quarter. Entropy Technologies LP bought a new position in TransMedics Group in the first quarter worth about $201,000. ProShare Advisors LLC lifted its position in shares of TransMedics Group by 7.8% during the first quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock valued at $434,000 after buying an additional 427 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in shares of TransMedics Group by 337,462.5% in the 1st quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after buying an additional 26,997 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on TMDX. TD Cowen raised their price objective on shares of TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Morgan Stanley boosted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Piper Sandler reiterated an “overweight” rating and set a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research note on Wednesday, May 1st. Finally, Oppenheimer boosted their price target on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.